# Ziprasidone Pharmacokinetics Using a Reduced Food Effect Formulation Compared to Pharmacokinetics From Commercial Capsules

> **NCT00821444** · PHASE1 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 11 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ziprasidone
- **DRUG:** B16 Fasted
- **DRUG:** B16 Fed

## Key facts

- **NCT ID:** NCT00821444
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00821444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00821444, "Ziprasidone Pharmacokinetics Using a Reduced Food Effect Formulation Compared to Pharmacokinetics From Commercial Capsules". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00821444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*